Meeting Abstract
Hematologic Malignancies: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner
Amber B. Koehler, PA-C, MS, P. Andrew Allred, MS, PA-C, and Donna Catamero, ANP-BC, OCN®, CCRC
Mayo Clinic, Banner MD Anderson Cancer Center, and Mount Sinai Hospital
J Adv Pract Oncol 2021;12(6):635-646 |
https://doi.org/10.6004/jadpro.2021.12.6.11 |
© 2021 Harborside™
ABSTRACT
With conference reporting provided by The ASCO Post, Amber B. Koehler, PA-C, MS, of Mayo Clinic, evaluates data on BTK inhibitors; fixed-duration, first-line treatment with ibrutinib plus venetoclax; and a novel oral BCL2 antagonist for patients with CLL. P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, reviews data on a front-line therapy for patients with Ph+ acute lymphoblastic leukemia and brexucabtagene autoleucel, an anti-CD19 CAR T-cell therapy. Donna Catamero, ANP-BC, OCN®, CCRC, of Mount Sinai Hospital, reflects on findings on a BCMA-directed CAR T-cell therapy and a bispecific monoclonal antibody for patients with multiple myeloma.
For access to the full length article, please
sign in.
